| Literature DB >> 35533463 |
Pedro Rodrigues1, Rafael S Costa2, Rui Henriques3.
Abstract
STATEMENT: Enrichment analysis of cell transcriptional responses to SARS-CoV-2 infection from biclustering solutions yields broader coverage and superior enrichment of GO terms and KEGG pathways against alternative state-of-the-art machine learning solutions, thus aiding knowledge extraction. MOTIVATION AND METHODS: The comprehensive understanding of the impacts of SARS-CoV-2 virus on infected cells is still incomplete. This work aims at comparing the role of state-of-the-art machine learning approaches in the study of cell regulatory processes affected and induced by the SARS-CoV-2 virus using transcriptomic data from both infectable cell lines available in public databases and in vivo samples. In particular, we assess the relevance of clustering, biclustering and predictive modeling methods for functional enrichment. Statistical principles to handle scarcity of observations, high data dimensionality, and complex gene interactions are further discussed. In particular, and without loos of generalization ability, the proposed methods are applied to study the differential regulatory response of lung cell lines to SARS-CoV-2 (α-variant) against RSV, IAV (H1N1), and HPIV3 viruses.Entities:
Keywords: Biclustering; COVID-19; Computational biology; Discriminative regulatory patterns; Machine learning; SARS-CoV-2; Transcriptomics
Mesh:
Year: 2022 PMID: 35533463 PMCID: PMC9040465 DOI: 10.1016/j.compbiomed.2022.105443
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 6.698
Fig. 1Overview of the structure of the dataset used in this study. Numbers between parentheses represent the number of data points.
Fig. 2Distribution of gene expression (mean among samples) after applying a log2 transform (N = 21797 genes).
Fig. 3Variability of gene expression within healthy and within infected cells.
Tested pairs of conditions.
| NHBE Healthy | NHBE SARS-CoV-2 |
| NHBE Healthy | NHBE IAV |
| NHBE Healthy | NHBE IAVdNS1 |
| A549 Healthy | A549 SARS-CoV-2 |
| A549 Healthy | A549 IAV |
| A549 Healthy | A549 RSV |
| A549 Healthy | A549 HPIV3 |
| Calu3 Healthy | Calu3 SARS-CoV-2 |
| Biopsy Healthy | Biopsy SARS-CoV-2 |
Fig. 4Schematic diagram of the steps composing the proposed computational pipeline.
Fig. 5Biclustering with constant and order-preserving coherence assumptions. The illustrative constant bicluster has pattern (value expectations) φ = {c1 = 1.1, c2 = 0.45, c3 = 0.9} on x2 and x3 observations, while the order-preserving bicluster satisfies the π= (g1 ≥ g3 ≥ g2) permutation on {x1, x2, x3} observations.
Top 15 GO biological processes ordered by combined score after selecting differentially expressed genes using the Multi-Condition Setting (p < 0.01). GO IDs are linked to descriptions of the biological processes in the QuickGO web browser.
| GO Biological Process | p-value | c-score |
|---|---|---|
| cellular response to type I interferon ( | 2.35E-10 | 324.03 |
| type I interferon signaling pathway ( | 2.35E-10 | 324.03 |
| cytokine-mediated signaling pathway ( | 3.80E-26 | 319.38 |
| protein mono-ADP-ribosylation ( | 3.22E-04 | 319.17 |
| receptor signaling pathway via STAT ( | 2.73E-06 | 299.82 |
| receptor signaling pathway via JAK-STAT ( | 2.50E-06 | 250.15 |
| exogenous peptide antigen, TAP-independent ( | 7.04E-03 | 219.44 |
| negative regulation of bone remodeling ( | 2.62E-03 | 212.68 |
| interferon-gamma-mediated signaling pathway ( | 3.48E-08 | 211.38 |
| cellular response to interferon-gamma ( | 5.98E-10 | 192.56 |
| cellular response to cytokine stimulus ( | 6.64E-16 | 177.02 |
| negative regulation of bone resorption ( | 9.92E-03 | 164.52 |
| positive regulation of tyrosine phosphorylation of STAT protein ( | 1.39E-06 | 163.05 |
| negative regulation of viral genome replication ( | 2.50E-06 | 159.30 |
| positive regulation of defense response ( | 6.15E-08 | 155.70 |
Top 20 GO biological processes ordered by combined score (clustering applied over the multi-condition gene selection setting, p < 0.01). See GO IDs for links to biological processes in the QuickGo web browser.
| GO Biological Process | ||
|---|---|---|
| type I interferon signaling pathway (GO:0060337) | 4.40E-27 | 9111.11 |
| cellular response to type I interferon (GO:0071357) | 4.40E-27 | 9111.11 |
| negative regulation of viral genome replication (GO:0045071) | 1.10E-16 | 3820.31 |
| defense response to symbiont (GO:0140546) | 7.74E-22 | 3260.22 |
| cytoplasmic PRR signaling pathway | 1.74E-06 | 3253.53 |
| negative regulation of viral process (GO:0048525) | 5.16E-17 | 3163.10 |
| defense response to virus (GO:0051607) | 2.34E-21 | 2930.10 |
| endogenous peptide antigen, TAP-independent (GO:0002486) | 4.42E-05 | 2797.75 |
| endogenous peptide antigen (GO:0002484) | 4.42E-05 | 2797.75 |
| regulation of viral genome replication (GO:0045069) | 1.64E-15 | 2717.94 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 1.79E-15 | 2656.13 |
| protein mono-ADP-ribosylation (GO:0140289) | 3.35E-06 | 2318.71 |
| exogenous peptide antigen, TAP-independent (GO:0002480) | 6.69E-05 | 2159.41 |
| cellular response to interferon-gamma (GO:0071346) | 5.16E-17 | 2028.44 |
| negative regulation of lipid localization (GO:1905953) | 8.90E-05 | 1742.91 |
| response to interferon-beta (GO:0035456) | 6.88E-08 | 1678.71 |
| regulation of ribonuclease activity (GO:0060700) | 1.81E-03 | 1644.95 |
| positive regulation of glial cell proliferation (GO:0060252) | 1.81E-03 | 1644.95 |
| interleukin-27-mediated signaling pathway (GO:0070106) | 7.76E-06 | 1582.01 |
| cytokine-mediated signaling pathway (GO:0019221) | 6.11E-25 | 1457.27 |
Some names have been shortened in favor of succinctness, with full definitions available in the accompanying hyperlink.
Top 20 KEGG pathways ordered by combined score for A549 cells (paired healthy versus SARS-CoV-2 setting). See KEGG IDs for links to the pathway maps description.
| Measles (map05162) | 1.02E-08 | 295.14 |
| Influenza A (map05164) | 1.02E-08 | 252.18 |
| Herpes simplex virus 1 infection (map05168) | 7.16E-10 | 177.20 |
| Epstein-Barr virus infection (map05169) | 4.82E-07 | 156.14 |
| TNF signaling pathway (map04668) | 1.11E-07 | 153.86 |
| Coronavirus disease (map05171) | 3.78E-07 | 150.32 |
| RIG-I-like receptor signaling pathway (map04622) | 3.68E-04 | 120.34 |
| NOD-like receptor signaling pathway (map04621) | 9.37E-06 | 119.63 |
| Legionellosis (map05134) | 1.77E-05 | 118.99 |
| Hepatitis C (map05160) | 1.79E-05 | 118.31 |
| TNF signaling pathway (map04668) | 8.61E-05 | 116.25 |
| Primary immunodeficiency (map05340) | 2.17E-03 | 116.00 |
| Allograft rejection (map05330) | 2.17E-03 | 116.00 |
| Amoebiasis (map05146) | 2.13E-06 | 111.38 |
| African trypanosomiasis (map05143) | 1.50E-04 | 111.14 |
| Rheumatoid arthritis (map05323) | 3.12E-06 | 110.93 |
| Legionellosis (map05134) | 1.12E-03 | 105.75 |
| Antigen processing and presentation (map04612) | 5.58E-04 | 100.66 |
| JAK-STAT signaling pathway (map04630) | 1.07E-06 | 96.92 |
| NF-kappa B signaling pathway (map04064) | 3.68E-04 | 92.76 |
Top 20 GO biological processes ordered by combined score using Random Forest (Multi-Condition Setting, p < 0.01).
| GO Biological Processes | p-value | c-score |
|---|---|---|
| protein mono-ADP-ribosylation (GO:0140289) | 3.44E-06 | 980.50 |
| type I interferon signaling pathway (GO:0060337) | 3.70E-14 | 833.99 |
| cellular response to type I interferon (GO:0071357) | 3.70E-14 | 833.99 |
| regulation of fever generation (GO:0031620) | 2.02E-03 | 819.46 |
| positive regulation of glial cell proliferation (GO:0060252) | 2.02E-03 | 819.46 |
| cytokine-mediated signaling pathway (GO:0019221) | 7.67E-24 | 420.28 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 3.65E-09 | 372.42 |
| negative regulation of viral genome replication (GO:0045071) | 3.35E-08 | 368.56 |
| antigen processing via MHC class I via ER pathway (GO:0002484) | 5.02E-03 | 358.52 |
| antigen processing via MHC class I via ER, TAP-independent (GO:0002486) | 5.02E-03 | 358.52 |
| positive regulation of gliogenesis (GO:0014015) | 5.02E-03 | 358.52 |
| positive regulation of podosome assembly (GO:0071803) | 5.02E-03 | 358.52 |
| cellular response to interferon-gamma (GO:0071346) | 1.87E-11 | 354.96 |
| negative regulation of viral process (GO:0048525) | 4.92E-09 | 353.10 |
| interleukin-27-mediated signaling pathway (GO:0070106) | 3.24E-04 | 344.30 |
| defense response to symbiont (GO:0140546) | 2.53E-11 | 339.26 |
| receptor signaling pathway via STAT (GO:0097696) | 2.01E-05 | 337.92 |
| positive regulation of epidermal growth factor-activated receptor activity (GO:0045741) | 1.26E-03 | 332.52 |
| receptor signaling pathway via JAK-STAT (GO:0007259) | 6.49E-06 | 329.14 |
| defense response to virus (GO:0051607) | 8.56E-11 | 297.98 |
Top 20 GO biological processes ordered by combined score using XGBoost (Multi-Condition Setting, p < 0.01).
| GO Biological Processes | p-value | c-score |
|---|---|---|
| ISG15-protein conjugation (GO:0032020) | 7.61E-03 | 869.12 |
| macrophage chemotaxis (GO:0048246) | 1.20E-03 | 783.48 |
| response to interferon-gamma (GO:0034341) | 1.20E-07 | 672.59 |
| nicotinamide nucleotide biosynthetic process (GO:0019359) | 9.89E-03 | 666.41 |
| regulation of natural killer cell chemotaxis (GO:2000501) | 9.89E-03 | 666.41 |
| macrophage migration (GO:1905517) | 2.00E-03 | 548.36 |
| eosinophil migration (GO:0072677) | 2.01E-03 | 495.85 |
| eosinophil chemotaxis (GO:0048245) | 2.01E-03 | 495.85 |
| lymphocyte migration (GO:0072676) | 8.21E-05 | 435.11 |
| neutrophil chemotaxis (GO:0030593) | 8.53E-06 | 432.97 |
| chemokine-mediated signaling pathway (GO:0070098) | 2.76E-05 | 412.00 |
| granulocyte chemotaxis (GO:0071621) | 9.17E-06 | 406.08 |
| lymphocyte chemotaxis (GO:0048247) | 1.24E-04 | 376.49 |
| neutrophil migration (GO:1990266) | 1.11E-05 | 374.27 |
| cellular response to chemokine (GO:1990869) | 3.60E-05 | 370.93 |
| cellular response to interferon-gamma (GO:0071346) | 1.66E-06 | 355.72 |
| type I interferon signaling pathway (GO:0060337) | 4.53E-05 | 328.36 |
| cellular response to type I interferon (GO:0071357) | 4.53E-05 | 328.36 |
| NAD biosynthetic process (GO:0009435) | 3.89E-03 | 327.14 |
| monocyte chemotaxis (GO:0002548) | 2.00E-03 | 232.75 |
Statistics for comparing the performance of the tested biclustering algorithms with different preprocessing techniques. Note: corresponds to the number of biclusters; is the average number of genes per bicluster; σ|the standard deviation of genes per bicluster; the average number of conditions per bicluster; σ| the standard deviation of the number of conditions per bicluster; and finally the average number of enriched terms per bicluster.
| BicPAMS | 80 | 208.03 | 18.54 | 3.16 | 0.53 | 28.91 | |
| 79 | 3526.66 | 301.50 | 3.24 | 0.64 | 341.70 | ||
| ANOVA (top 200) | 7 | 188.29 | 5.95 | 10.00 | 9.70 | 10.57 | |
| ANOVA (top 1000) | 20 | 676.05 | 29.13 | 5.00 | 4.22 | 55.75 | |
| ANOVA (top 5000) | 57 | 2106.18 | 128.36 | 3.61 | 1.25 | 131.32 | |
| Cheng and Church | 50 | 15.60 | 12.59 | 12.92 | 5.90 | 3.46 | |
| 100 | 55.90 | 16.23 | 34.79 | 9.96 | 1.68 | ||
| ANOVA (top 200) | 8 | 25.00 | 23.49 | 21.38 | 12.56 | 6.50 | |
| ANOVA (top 1000) | 56 | 17.86 | 15.27 | 17.89 | 10.67 | 4.41 | |
| ANOVA (top 5000) | 100 | 34.54 | 24.10 | 22.76 | 11.25 | 2.47 | |
| Plaid | 10 | 64.70 | 55.53 | 14.20 | 5.60 | 29.90 | |
| 10 | 776.40 | 922.43 | 11.60 | 6.89 | 24.10 | ||
| ANOVA (top 200) | 8 | 44.00 | 30.76 | 12.88 | 8.43 | 9.88 | |
| ANOVA (top 1000) | 10 | 159.50 | 100.72 | 12.20 | 7.29 | 18.70 | |
| ANOVA (top 5000) | 10 | 739.20 | 530.04 | 13.10 | 7.48 | 43.40 | |
| xMotifs | 10 | 31.90 | 17.17 | 8.20 | 2.86 | 1.70 | |
| 10 | 654.50 | 365.82 | 6.00 | 0.00 | 6.30 | ||
| ANOVA (top 200) | 6 | 30.33 | 34.30 | 24.50 | 9.73 | 10.67 | |
| ANOVA (top 1000) | 10 | 71.90 | 103.54 | 11.10 | 4.28 | 7.60 | |
| ANOVA (top 5000) | 10 | 326.00 | 538.95 | 6.20 | 0.60 | 5.30 |
GO biological processes with highest joint ranks for SARS-CoV-2 conditions. Counts correspond to the normalized number of occurrences of each process within each condition.
| GO Biological Processes | A549 SARS-CoV-2 | NHBE SARS-CoV-2 | Calu3 SARS-CoV-2 | Biopsy SARS-CoV-2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | |
| cytokine-mediated signaling pathway (GO:0019221) | 1.00 | 6.95E-3 | 6.06E+5 | 0.75 | 2.79E-4 | 6.06E+5 | 1.00 | 2.29E-3 | 1.02E+3 | 0.60 | 2.79E-4 | 6.06E+5 |
| cellular response to interferon-gamma (GO:0071346) | 0.66 | 1.15E-7 | 5.61E+2 | 0.88 | 4.31E-3 | 3.97E+2 | 0.83 | 2.36E-4 | 1.13E+3 | 0.56 | 1.37E-18 | 1.56E+3 |
| cellular response to cytokine stimulus (GO:0071345) | 0.61 | 2.50E-4 | 6.55E+5 | 0.92 | 2.50E-4 | 6.55E+5 | 0.67 | 4.14E-4 | 3.67E+2 | 0.44 | 2.50E-4 | 6.55E+5 |
| inflammatory response (GO:0006954) | 0.45 | 5.30E-5 | 6.46E+2 | 0.75 | 3.90E-4 | 1.47E+2 | 0.50 | 3.23E-5 | 2.30E+2 | 0.72 | 3.23E-23 | 3.84E+2 |
| protein modification by small protein removal (GO:0070646) | 0.49 | 7.88E-3 | 1.74E+2 | 0.46 | 7.88E-3 | 1.68E+2 | 0.67 | 6.62E-3 | 1.39E+2 | 0.63 | 2.74E-4 | 1.25E+2 |
| regulation of immune response (GO:0050776) | 0.34 | 3.64E-7 | 7.11E+2 | 0.71 | 5.14E-3 | 1.85E+2 | 0.69 | 3.32E-3 | 2.62E+2 | 0.72 | 2.84E-25 | 5.29E+2 |
| mRNA splicing, via spliceosome (GO:0000398) | 0.51 | 2.08E-6 | 7.38E+2 | 0.62 | 1.69E-4 | 6.89E+2 | 0.42 | 3.83E-5 | 3.18E+2 | 0.65 | 1.11E-5 | 5.68E+2 |
| mRNA processing (GO:0006397) | 0.51 | 2.88E-6 | 7.02E+2 | 0.62 | 3.98E-4 | 6.99E+2 | 0.42 | 3.83E-5 | 3.67E+2 | 0.65 | 1.27E-5 | 6.39E+2 |
| DNA metabolic process (GO:0006259) | 0.45 | 5.44E-4 | 2.63E+2 | 0.38 | 7.56E-4 | 4.22E+1 | 0.22 | 7.56E-4 | 1.40E+2 | 1.00 | 2.59E-6 | 1.97E+2 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 0.54 | 1.03E-3 | 6.97E+2 | 0.38 | 9.63E-4 | 6.97E+2 | 0.75 | 1.14E-6 | 1.49E+3 | 0.21 | 5.67E-8 | 1.28E+3 |
| epidermis development (GO:0008544) | 0.54 | 1.83E-4 | 1.44E+3 | 0.88 | 2.21E-22 | 2.15E+3 | 0.08 | 8.41E-6 | 5.33E+2 | 0.35 | 6.74E-4 | 6.99E+2 |
| RNA splicing, with bulged adenosine as nucleophile (GO:0000377) | 0.48 | 3.31E-6 | 7.02E+2 | 0.62 | 4.30E-4 | 6.75E+2 | 0.42 | 3.83E-5 | 3.36E+2 | 0.56 | 1.27E-5 | 5.35E+2 |
| positive regulation of response to external stimulus (GO:0032103) | 0.39 | 3.65E-3 | 5.26E+2 | 0.67 | 1.82E-3 | 1.36E+2 | 0.69 | 8.96E-3 | 3.29E+2 | 0.35 | 2.81E-10 | 3.26E+2 |
| chemokine-mediated signaling pathway (GO:0070098) | 0.39 | 6.02E-5 | 3.99E+3 | 0.67 | 1.55E-4 | 5.04E+2 | 0.67 | 1.16E-3 | 4.40E+2 | 0.37 | 1.19E-8 | 4.94E+2 |
| DNA repair (GO:0006281) | 0.45 | 4.48E-3 | 3.13E+2 | 0.25 | 4.65E-3 | 3.81E+1 | 0.22 | 4.65E-3 | 1.36E+2 | 0.95 | 9.43E-3 | 1.36E+2 |
| extracellular matrix organization (GO:0030198) | 0.32 | 1.13E-3 | 1.05E+2 | 1.00 | 3.31E-8 | 1.70E+2 | 0.28 | 1.81E-3 | 6.33E+1 | 0.44 | 2.96E-6 | 9.18E+1 |
| neutrophil mediated immunity (GO:0002446) | 0.53 | 3.68E-3 | 2.39E+2 | 0.38 | 2.14E-24 | 1.93E+2 | 0.67 | 2.16E-5 | 2.48E+2 | 0.28 | 1.57E-8 | 1.12E+2 |
| cellular response to DNA damage stimulus (GO:0006974) | 0.47 | 2.65E-3 | 1.29E+2 | 0.29 | 4.65E-3 | 1.10E+2 | 0.11 | 2.73E-17 | 1.42E+2 | 0.95 | 6.21E-5 | 1.42E+2 |
| neutrophil activation involved in immune response (GO:0002283) | 0.49 | 6.01E-21 | 2.39E+2 | 0.50 | 9.44E-3 | 1.93E+2 | 0.67 | 2.16E-5 | 2.47E+2 | 0.28 | 4.96E-9 | 8.95E+1 |
| neutrophil degranulation (GO:0043312) | 0.49 | 2.12E-21 | 2.46E+2 | 0.50 | 8.99E-3 | 2.00E+2 | 0.67 | 2.16E-5 | 2.55E+2 | 0.26 | 5.39E-8 | 9.08E+1 |
| cellular response to chemokine (GO:1990869) | 0.36 | 8.06E-5 | 3.65E+3 | 0.62 | 1.94E-4 | 4.57E+2 | 0.72 | 1.75E-3 | 3.99E+2 | 0.26 | 4.05E-8 | 4.45E+2 |
| protein ubiquitination (GO:0016567) | 0.45 | 9.45E-3 | 1.70E+2 | 0.29 | 9.45E-3 | 1.70E+2 | 0.19 | 9.45E-3 | 8.06E+1 | 0.81 | 9.45E-3 | 1.55E+2 |
| cellular protein modification process (GO:0006464) | 0.49 | 1.52E-19 | 1.39E+2 | 0.29 | 1.93E-3 | 1.20E+2 | 0.25 | 1.93E-3 | 8.82E+1 | 0.70 | 2.97E-6 | 1.19E+2 |
| antigen receptor-mediated signaling pathway (GO:0050851) | 0.49 | 6.48E-6 | 8.87E+1 | 0.67 | 3.95E-3 | 8.87E+1 | 0.14 | 3.73E-6 | 1.63E+2 | 0.26 | 4.15E-11 | 1.63E+2 |
| defense response to symbiont (GO:0140546) | 0.39 | 7.76E-6 | 9.11E+5 | 0.38 | 7.76E-6 | 9.11E+5 | 0.75 | 1.15E-10 | 1.66E+3 | 0.23 | 7.76E-6 | 9.11E+5 |
Fig. 6Decision Tree for Multi-Condition Setting (p < 0.01) using Gini criterion. Colors represent each class (condition), with a node's color corresponding to the combination of the colors of all associated conditions.
GO biological processes with highest joint ranks for all viruses for the A549 cell type. Counts correspond to the normalized number of occurrences of each process within each condition.
| GO Biological Processes | A549 SARS-CoV-2 | A549 RSV | A549 HPIV3 | A549 IAV | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | |
| epidermis development (GO:0008544) | 0.54 | 1.83E-4 | 1.44E+3 | 1.00 | 4.96E-6 | 7.01E+2 | 1.00 | 1.83E-4 | 1.44E+3 | 1.00 | 2.38E-14 | 9.94E+2 |
| cellular response to interferon-gamma (GO:0071346) | 0.66 | 1.15E-7 | 5.61E+2 | 0.85 | 1.15E-7 | 2.91E+2 | 0.92 | 1.15E-7 | 7.32E+2 | 0.86 | 4.74E-6 | 2.91E+2 |
| cytokine-mediated signaling pathway (GO:0019221) | 1.00 | 6.95E-3 | 6.06E+5 | 0.74 | 6.95E-3 | 9.57E+1 | 0.90 | 6.95E-3 | 4.40E+2 | 1.00 | 2.87E-10 | 4.36E+2 |
| inflammatory response (GO:0006954) | 0.45 | 5.30E-5 | 6.46E+2 | 0.97 | 1.23E-7 | 2.33E+2 | 0.92 | 5.30E-5 | 1.97E+2 | 1.00 | 3.90E-4 | 2.53E+2 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 0.54 | 1.03E-3 | 6.97E+2 | 0.74 | 1.03E-3 | 2.19E+2 | 0.92 | 1.03E-3 | 9.72E+2 | 0.61 | 8.73E-3 | 2.19E+2 |
| antigen receptor-mediated signaling pathway (GO:0050851) | 0.49 | 6.48E-6 | 8.87E+1 | 0.68 | 2.38E-4 | 8.87E+1 | 0.63 | 6.48E-6 | 8.87E+1 | 0.59 | 1.92E-3 | 8.87E+1 |
| complement activation, classical pathway (GO:0006958) | 0.39 | 6.59E-3 | 8.66E+3 | 0.91 | 4.52E-5 | 8.66E+3 | 0.86 | 6.59E-3 | 8.66E+3 | 0.78 | 4.54E-5 | 8.66E+3 |
| skin development (GO:0043588) | 0.46 | 9.85E-4 | 3.80E+2 | 0.71 | 8.82E-6 | 3.80E+2 | 0.59 | 4.62E-4 | 3.80E+2 | 0.57 | 9.85E-4 | 3.80E+2 |
| cellular response to cytokine stimulus (GO:0071345) | 0.61 | 2.50E-4 | 6.55E+5 | 0.41 | 5.74E-5 | 8.36E+1 | 0.55 | 5.74E-5 | 1.49E+2 | 0.71 | 5.74E-5 | 1.69E+2 |
| chemokine-mediated signaling pathway (GO:0070098) | 0.39 | 6.02E-5 | 3.99E+3 | 0.76 | 6.02E-5 | 5.04E+2 | 0.71 | 6.02E-5 | 8.65E+2 | 0.67 | 7.71E-3 | 5.04E+2 |
| humoral immune response via immunoglobulin (GO:0002455) | 0.37 | 8.06E-5 | 5.89E+3 | 0.91 | 8.06E-5 | 5.89E+3 | 0.82 | 8.06E-5 | 5.89E+3 | 0.76 | 5.90E-5 | 5.89E+3 |
| positive regulation of external stimulus response (GO:0032103) | 0.39 | 3.65E-3 | 5.26E+2 | 0.56 | 3.65E-3 | 1.43E+2 | 0.71 | 3.65E-3 | 1.95E+2 | 0.76 | 4.51E-3 | 1.47E+2 |
| epidermal cell differentiation (GO:0009913) | 0.36 | 9.67E-4 | 9.29E+2 | 0.88 | 1.21E-7 | 9.29E+2 | 0.71 | 8.76E-5 | 9.29E+2 | 0.76 | 9.67E-4 | 9.29E+2 |
| keratinocyte differentiation (GO:0030216) | 0.36 | 1.51E-3 | 1.29E+3 | 0.85 | 1.31E-6 | 1.29E+3 | 0.71 | 6.21E-4 | 1.29E+3 | 0.76 | 1.51E-3 | 1.29E+3 |
| regulation of immune response (GO:0050776) | 0.34 | 3.64E-7 | 7.11E+2 | 0.94 | 3.06E-9 | 7.11E+2 | 0.88 | 3.64E-7 | 2.29E+2 | 0.88 | 1.18E-8 | 7.11E+2 |
| cellular response to chemokine (GO:1990869) | 0.36 | 8.06E-5 | 3.65E+3 | 0.68 | 8.06E-5 | 4.57E+2 | 0.67 | 8.06E-5 | 7.92E+2 | 0.59 | 1.94E-4 | 4.57E+2 |
| positive regulation of defense response (GO:0031349) | 0.36 | 2.07E-3 | 8.24E+2 | 0.38 | 2.07E-3 | 1.36E+2 | 0.45 | 2.07E-3 | 2.17E+2 | 0.75 | 2.07E-3 | 1.37E+2 |
| exogenous peptide antigen via MHC class II (GO:0019886) | 0.48 | 6.36E-3 | 6.51E+2 | 0.41 | 6.36E-3 | 6.51E+2 | 0.43 | 6.36E-3 | 6.51E+2 | 0.29 | 9.02E-3 | 6.51E+2 |
| peptide antigen via MHC class II (GO:0002495) | 0.48 | 6.81E-3 | 6.34E+2 | 0.38 | 6.81E-3 | 6.34E+2 | 0.43 | 6.81E-3 | 6.34E+2 | 0.27 | 9.02E-3 | 6.34E+2 |
| positive regulation of chemotaxis (GO:0050921) | 0.31 | 6.20E-4 | 3.42E+2 | 0.88 | 3.37E-3 | 3.42E+2 | 0.80 | 6.20E-4 | 4.14E+2 | 0.82 | 6.71E-3 | 3.42E+2 |
| extracellular matrix organization (GO:0030198) | 0.32 | 1.13E-3 | 1.05E+2 | 0.53 | 1.13E-3 | 3.98E+1 | 0.59 | 1.13E-3 | 3.90E+1 | 0.57 | 1.13E-3 | 4.23E+1 |
| T cell receptor signaling pathway (GO:0050852) | 0.41 | 2.70E-3 | 1.16E+2 | 0.29 | 8.46E-4 | 5.79E+1 | 0.35 | 2.70E-3 | 6.64E+1 | 0.24 | 2.46E-3 | 3.68E+1 |
| presentation of exogenous peptide antigen (GO:0002478) | 0.45 | 7.80E-3 | 6.10E+2 | 0.26 | 7.80E-3 | 6.10E+2 | 0.31 | 7.80E-3 | 6.10E+2 | 0.16 | 9.02E-3 | 6.10E+2 |
| positive regulation of protein phosphorylation (GO:0001934) | 0.33 | 4.81E-3 | 5.19E+1 | 0.32 | 4.81E-3 | 5.19E+1 | 0.29 | 4.81E-3 | 5.19E+1 | 0.31 | 5.56E-3 | 5.19E+1 |
| mRNA processing (GO:0006397) | 0.51 | 2.88E-6 | 7.02E+2 | 0.18 | 2.34E-8 | 3.67E+2 | 0.29 | 3.83E-5 | 5.11E+2 | 0.20 | 2.88E-6 | 3.67E+2 |
GO Biological processes with highest joint ranks for all viruses for the NHBE cell type. Counts correspond to the normalized number of occurrences of each process within each condition.
| GO Biological Processes | NHBE SARS-CoV-2 | NHBE IAV | NHBE IAVdNS1 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | |
| extracellular matrix organization (GO:0030198) | 1.00 | 3.31E-08 | 1.70E+02 | 1.00 | 3.31E-08 | 1.70E+02 | 0.84 | 3.31E-08 | 1.70E+02 |
| cardiac muscle tissue development (GO:0048738) | 0.79 | 4.78E-03 | 3.00E+02 | 0.91 | 4.78E-03 | 3.00E+02 | 0.80 | 4.78E-03 | 3.00E+02 |
| inflammatory response (GO:0006954) | 0.75 | 3.90E-04 | 1.47E+02 | 0.91 | 3.90E-04 | 2.71E+02 | 1.00 | 3.90E-04 | 2.71E+02 |
| dendritic cell migration (GO:0036336) | 0.75 | 6.79E-03 | 5.92E+02 | 0.86 | 6.79E-03 | 5.92E+02 | 0.77 | 6.79E-03 | 5.92E+02 |
| dendritic cell chemotaxis (GO:0002407) | 0.75 | 6.71E-03 | 7.08E+02 | 0.86 | 6.71E-03 | 7.08E+02 | 0.77 | 6.71E-03 | 7.08E+02 |
| cellular response to interferon-gamma (GO:0071346) | 0.88 | 4.31E-03 | 3.97E+02 | 0.79 | 4.31E-03 | 5.12E+02 | 0.75 | 7.60E-04 | 1.13E+03 |
| extracellular structure organization (GO:0043062) | 0.75 | 1.10E-07 | 8.85E+01 | 0.86 | 1.10E-07 | 8.85E+01 | 0.70 | 1.10E-07 | 8.85E+01 |
| external encapsulating structure organization (GO:0045229) | 0.75 | 4.67E-08 | 9.64E+01 | 0.86 | 4.67E-08 | 9.64E+01 | 0.70 | 4.67E-08 | 9.64E+01 |
| regulation of immune response (GO:0050776) | 0.71 | 5.14E-03 | 1.85E+02 | 0.79 | 5.14E-03 | 1.85E+02 | 0.82 | 5.14E-03 | 1.85E+02 |
| negative regulation of T cell activation (GO:0050868) | 0.75 | 9.83E-03 | 1.13E+03 | 0.77 | 3.11E-03 | 4.28E+02 | 0.66 | 3.11E-03 | 4.28E+02 |
| phospholipase receptor signaling pathway (GO:0007200) | 0.67 | 9.33E-03 | 2.60E+02 | 0.81 | 9.33E-03 | 2.60E+02 | 0.66 | 9.33E-03 | 2.60E+02 |
| regulation of T cell proliferation (GO:0042129) | 0.67 | 7.93E-04 | 4.13E+02 | 0.77 | 7.93E-04 | 4.13E+02 | 0.66 | 7.93E-04 | 4.13E+02 |
| chemokine-mediated signaling pathway (GO:0070098) | 0.67 | 1.55E-04 | 5.04E+02 | 0.67 | 1.55E-04 | 5.04E+02 | 0.68 | 4.01E-04 | 5.04E+02 |
| positive regulation of chemotaxis (GO:0050921) | 0.62 | 6.71E-03 | 3.42E+02 | 0.79 | 6.71E-03 | 9.51E+02 | 0.59 | 6.71E-03 | 9.51E+02 |
| cellular response to cytokine stimulus (GO:0071345) | 0.92 | 2.50E-04 | 6.55E+05 | 0.70 | 2.90E-03 | 1.42E+02 | 0.52 | 2.90E-03 | 2.98E+02 |
| positive regulation of lymphocyte proliferation (GO:0050671) | 0.54 | 3.72E-03 | 1.66E+02 | 0.70 | 3.72E-03 | 1.66E+02 | 0.70 | 8.75E-03 | 3.05E+02 |
| complement activation, classical pathway (GO:0006958) | 0.58 | 4.54E-05 | 8.66E+03 | 0.70 | 4.54E-05 | 9.67E+03 | 0.61 | 4.54E-05 | 9.67E+03 |
| nervous system development (GO:0007399) | 0.54 | 3.84E-03 | 3.69E+01 | 0.74 | 3.84E-03 | 3.74E+01 | 0.61 | 3.84E-03 | 3.56E+01 |
| heart development (GO:0007507) | 0.54 | 2.69E-03 | 7.04E+01 | 0.74 | 2.69E-03 | 7.04E+01 | 0.61 | 2.69E-03 | 7.04E+01 |
| positive regulation of MAPK cascade (GO:0043410) | 0.54 | 9.24E-06 | 2.95E+02 | 0.70 | 9.24E-06 | 2.95E+02 | 0.66 | 9.24E-06 | 2.95E+02 |
| cellular response to chemokine (GO:1990869) | 0.62 | 1.94E-04 | 4.57E+02 | 0.63 | 1.94E-04 | 4.57E+02 | 0.75 | 4.14E-04 | 4.57E+02 |
| regulation of calcium ion-dependent exocytosis (GO:0017158) | 0.54 | 4.08E-03 | 1.91E+02 | 0.72 | 4.08E-03 | 1.91E+02 | 0.59 | 4.08E-03 | 1.91E+02 |
| positive regulation of ERK1 and ERK2 cascade (GO:0070374) | 0.54 | 6.12E-05 | 2.77E+02 | 0.70 | 6.12E-05 | 2.77E+02 | 0.61 | 6.12E-05 | 2.77E+02 |
| B cell receptor signaling pathway (GO:0050853) | 0.54 | 7.09E-04 | 5.07E+02 | 0.70 | 7.09E-04 | 5.07E+02 | 0.61 | 7.09E-04 | 5.07E+02 |
| calcium-mediated signaling (GO:0019722) | 0.54 | 6.85E-03 | 1.07E+02 | 0.70 | 6.85E-03 | 1.07E+02 | 0.61 | 6.85E-03 | 1.07E+02 |
Overview of the number of processes found, for different p values and for each of the methods applied (Multi-Condition Setting).
| Clustering | MCS (p < 0.01) | 463 | 215 | 76 |
| NHBE | 234 | 75 | 20 | |
| A549 | 182 | 38 | 19 | |
| Random Forests | MCS (p < 0.01) | 215 | 109 | 44 |
| NHBE | 110 | 22 | 3 | |
| A549 | 21 | 0 | 0 | |
| xGBoost | MCS (p < 0.01) | 60 | 41 | 15 |
| NHBE | 34 | 0 | 0 | |
| A549 | 36 | 0 | 0 | |
| BicPAMS | MCS (p < 0.01) | 4440 | 2086 | 1184 |
| NHBE | 2912 | 685 | 305 | |
| A549 | 3926 | 779 | 273 | |
Top GO biological processes ordered by combined score, for NHBE cells.
| GO Biological Process | Cluster | ||
|---|---|---|---|
| regulation of calcidiol 1-monooxygenase activity (GO:0060558) | 1.83E-03 | 1610.66 | 1 |
| pantothenate metabolic process (GO:0015939) | 1.83E-03 | 1610.66 | 1 |
| cellular response to type I interferon (GO:0071357) | 1.95E-12 | 1330.17 | 2 |
| type I interferon signaling pathway (GO:0060337) | 1.95E-12 | 1330.17 | 2 |
| postsynaptic neurotransmitter receptor internalization (GO:0098884) | 9.96E-03 | 865.07 | 2 |
| postsynaptic endocytosis (GO:0140239) | 9.96E-03 | 865.07 | 2 |
| regulation of ribonuclease activity (GO:0060700) | 9.96E-03 | 865.07 | 2 |
| response to interferon-beta (GO:0035456) | 2.28E-06 | 830.41 | 2 |
| defense response to symbiont (GO:0140546) | 9.02E-12 | 717.21 | 2 |
| defense response to virus (GO:0051607) | 1.94E-11 | 641.59 | 2 |
| response to interferon-alpha (GO:0035455) | 2.93E-04 | 593.97 | 2 |
| negative regulation of viral genome replication (GO:0045071) | 4.90E-06 | 434.32 | 2 |
| regulation of lipid storage (GO:0010883) | 5.88E-04 | 430.27 | 2 |
| antiviral innate immune response (GO:0140374) | 3.39E-03 | 426.70 | 2 |
| cytokine-mediated signaling pathway (GO:0019221) | 9.05E-15 | 395.62 | 2 |
| interleukin-27-mediated signaling pathway (GO:0070106) | 3.68E-03 | 382.07 | 2 |
| negative regulation of type I interferon-mediated signaling pathway (GO:0060339) | 4.10E-03 | 344.91 | 2 |
| negative regulation of chemokine production (GO:0032682) | 4.81E-03 | 313.53 | 2 |
| regulation of viral genome replication (GO:0045069) | 2.03E-05 | 309.60 | 2 |
| negative regulation of viral process (GO:0048525) | 2.50E-05 | 289.01 | 2 |
| regulation of complement activation (GO:0030449) | 1.88E-03 | 233.87 | 1 |
| regulation of lipid storage (GO:0010883) | 9.15E-03 | 233.65 | 1 |
| inflammatory response (GO:0006954) | 3.32E-07 | 215.82 | 2 |
| positive regulation of NIK/NF-kappaB signaling (GO:1901224) | 1.88E-03 | 213.72 | 1 |
| cellular response to virus (GO:0098586) | 2.89E-03 | 208.65 | 2 |
Top GO biological processes ordered by combined score, for A549 cells.
| GO Biological Process | Cluster | ||
|---|---|---|---|
| cellular response to type I interferon (GO:0071357) | 2.23E-15 | 1540.94 | 2 |
| type I interferon signaling pathway (GO:0060337) | 2.23E-15 | 1540.94 | 2 |
| negative regulation of viral genome replication (GO:0045071) | 3.07E-09 | 792.37 | 2 |
| response to interferon-beta (GO:0035456) | 4.98E-05 | 637.94 | 2 |
| negative regulation of viral life cycle (GO:1903901) | 1.99E-08 | 569.74 | 2 |
| regulation of viral genome replication (GO:0045069) | 2.32E-08 | 540.29 | 2 |
| regulation of interferon-alpha production (GO:0032647) | 6.90E-04 | 472.38 | 2 |
| positive regulation of interferon-alpha production (GO:0032727) | 1.26E-03 | 354.12 | 2 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 1.05E-06 | 344.39 | 2 |
| cytokine-mediated signaling pathway (GO:0019221) | 2.23E-15 | 327.50 | 2 |
| cellular response to interferon-gamma (GO:0071346) | 4.59E-08 | 321.58 | 2 |
| positive regulation of defense response to virus by host (GO:0002230) | 1.81E-03 | 300.45 | 2 |
| STAT cascade (GO:0097696) | 9.26E-04 | 211.79 | 0 |
| chemokine-mediated signaling pathway (GO:0070098) | 4.73E-04 | 195.27 | 2 |
| response to interferon-gamma (GO:0034341) | 1.78E-04 | 187.71 | 2 |
| regulation of leukocyte chemotaxis (GO:0002688) | 5.77E-03 | 169.19 | 2 |
| regulation of defense response to virus by host (GO:0050691) | 5.77E-03 | 169.19 | 2 |
| negative regulation of type I interferon production (GO:0032480) | 2.18E-03 | 160.73 | 2 |
| response to cytokine (GO:0034097) | 3.49E-05 | 147.64 | 2 |
| positive regulation of JAK-STAT cascade (GO:0046427) | 1.26E-03 | 139.37 | 2 |
| regulation of type I interferon production (GO:0032479) | 6.82E-04 | 130.07 | 2 |
| neutrophil migration (GO:1990266) | 6.25E-03 | 102.79 | 2 |
| JAK-STAT cascade (GO:0007259) | 4.73E-03 | 95.44 | 0 |
| positive regulation of leukocyte chemotaxis (GO:0002690) | 7.10E-03 | 94.66 | 2 |
| positive regulation of type I interferon production (GO:0032481) | 7.40E-03 | 92.17 | 2 |
Top GO biological processes ordered by combined score, for A549-ACE2 cells.
| GO Biological Process | Cluster | ||
|---|---|---|---|
| positive regulation of heat generation (GO:0031652) | 8.32E-03 | 3921.08 | 0 |
| regulation of fever generation (GO:0031620) | 8.32E-03 | 3921.08 | 0 |
| positive regulation of fever generation (GO:0031622) | 8.32E-03 | 2825.38 | 0 |
| regulation of vascular wound healing (GO:0061043) | 8.32E-03 | 1765.21 | 0 |
| positive regulation of steroid biosynthetic process (GO:0010893) | 8.32E-03 | 1765.21 | 0 |
| aerobic electron transport chain (GO:0019646) | 3.06E-20 | 833.55 | 2 |
| mitochondrial ATP synthesis coupled electron transport (GO:0042775) | 3.06E-20 | 801.88 | 2 |
| mitochondrial electron transport, NADH to ubiquinone (GO:0006120) | 2.72E-13 | 692.38 | 2 |
| 4.28E-03 | 637.69 | 2 | |
| amino acid catabolic process (GO:1902222) | 4.28E-03 | 637.69 | 2 |
| ribose phosphate metabolic process (GO:0019693) | 4.28E-03 | 637.69 | 2 |
| quinone catabolic process (GO:1901662) | 4.28E-03 | 637.69 | 2 |
| cellular glucuronidation (GO:0052695) | 9.25E-03 | 426.04 | 1 |
| acyl-CoA biosynthetic process (GO:0071616) | 2.56E-05 | 292.54 | 2 |
| acetyl-CoA biosynthetic process (GO:0006085) | 7.63E-04 | 291.06 | 2 |
| NADH dehydrogenase complex assembly (GO:0010257) | 3.07E-10 | 286.82 | 2 |
| mitochondrial respiratory chain complex I assembly (GO:0032981) | 3.07E-10 | 286.82 | 2 |
| mitochondrial respiratory chain complex assembly (GO:0033108) | 4.09E-10 | 198.40 | 2 |
| 5.27E-03 | 194.75 | 2 | |
| secondary alcohol biosynthetic process (GO:1902653) | 8.13E-06 | 177.46 | 2 |
| mitochondrial electron transport (GO:0006122) | 2.48E-03 | 171.57 | 2 |
| cholesterol biosynthetic process (GO:0006695) | 1.04E-05 | 165.42 | 2 |
| heme biosynthetic process (GO:0006783) | 2.74E-04 | 148.92 | 2 |
| fatty-acyl-CoA metabolic process (GO:0035337) | 2.74E-04 | 148.92 | 2 |
| sterol biosynthetic process (GO:0016126) | 2.56E-05 | 135.90 | 2 |
Table 15Top GO biological processes ordered by combined score, for Calu3 cells.
| GO Biological Process | Cluster | ||
|---|---|---|---|
| secondary alcohol biosynthetic process (GO:1902653) | 7.95E-16 | 1990.21 | 0 |
| regulation of ribonuclease activity (GO:0060700) | 7.19E-05 | 1921.48 | 2 |
| negative regulation of viral process (GO:0048525) | 2.57E-26 | 1907.45 | 2 |
| negative regulation of viral genome replication (GO:0045071) | 8.48E-23 | 1896.45 | 2 |
| cholesterol biosynthetic process (GO:0006695) | 7.95E-16 | 1858.91 | 0 |
| sterol biosynthetic process (GO:0016126) | 2.75E-15 | 1541.71 | 0 |
| defense response to symbiont (GO:0140546) | 9.30E-31 | 1498.91 | 2 |
| type I interferon signaling pathway (GO:0060337) | 7.48E-22 | 1405.26 | 2 |
| cellular response to type I interferon (GO:0071357) | 7.48E-22 | 1405.26 | 2 |
| defense response to virus (GO:0051607) | 9.30E-31 | 1396.78 | 2 |
| regulation of viral genome replication (GO:0045069) | 9.17E-19 | 1016.38 | 2 |
| regulation of nuclease activity (GO:0032069) | 1.78E-04 | 880.78 | 2 |
| positive regulation of extrinsic apoptotic signaling pathway (GO:1902043) | 1.78E-04 | 880.78 | 2 |
| cytokine-mediated signaling pathway (GO:0019221) | 9.36E-44 | 869.33 | 2 |
| isopentenyl diphosphate biosynthetic process (GO:0009240) | 6.97E-03 | 735.60 | 0 |
| negative regulation of lymphocyte differentiation (GO:0045620) | 3.64E-04 | 546.31 | 2 |
| positive regulation of gliogenesis (GO:0014015) | 3.64E-04 | 546.31 | 2 |
| positive regulation of smooth muscle cell differentiation (GO:1905065) | 3.64E-04 | 546.31 | 2 |
| negative regulation of innate immune response (GO:0045824) | 9.07E-10 | 500.91 | 2 |
| cellular response to interferon-gamma (GO:0071346) | 2.10E-16 | 485.61 | 2 |
| cellular response to cytokine stimulus (GO:0071345) | 3.66E-28 | 483.06 | 2 |
| positive regulation of heat generation (GO:0031652) | 2.52E-03 | 479.71 | 2 |
| exocyst localization (GO:0051601) | 2.52E-03 | 479.71 | 2 |
| regulation of fever generation (GO:0031620) | 2.52E-03 | 479.71 | 2 |
| positive regulation of glial cell proliferation (GO:0060252) | 2.52E-03 | 479.71 | 2 |
Top statistically relevant GO biological processes ordered by combined score for NHBE cells using Random Forests.
| GO Biological Processes | ||
|---|---|---|
| positive regulation of monocyte chemotactic protein-1 production (GO:0071639) | 4.06E-03 | 718.81 |
| chronic inflammatory response (GO:0002544) | 2.24E-02 | 558.06 |
| positive regulation of glial cell proliferation (GO:0060252) | 2.24E-02 | 558.06 |
| positive regulation of heat generation (GO:0031652) | 2.24E-02 | 558.06 |
| response to salt stress (GO:0009651) | 2.24E-02 | 558.06 |
| regulation of fever generation (GO:0031620) | 2.24E-02 | 558.06 |
| regulation of monocyte chemotactic protein-1 production (GO:0071637) | 8.10E-03 | 402.78 |
| positive regulation of fever generation (GO:0031622) | 2.70E-02 | 395.36 |
| ISG15-protein conjugation (GO:0032020) | 2.70E-02 | 395.36 |
| positive regulation of histone phosphorylation (GO:0033129) | 2.70E-02 | 395.36 |
| toll-like receptor 4 signaling pathway (GO:0034142) | 3.02E-03 | 312.35 |
| positive regulation of gliogenesis (GO:0014015) | 3.17E-02 | 300.93 |
| regulation of calcidiol 1-monooxygenase activity (GO:0060558) | 3.17E-02 | 300.93 |
| negative regulation of MyD88-independent toll-like receptor signaling (GO:0034128) | 3.17E-02 | 300.93 |
| intermediate filament bundle assembly (GO:0045110) | 3.17E-02 | 300.93 |
| positive regulation of granulocyte macrophage colony-stimulating factor (GO:0032725) | 1.33E-02 | 268.34 |
| interleukin-21-mediated signaling pathway (GO:0038114) | 3.55E-02 | 239.87 |
| cellular response to interleukin-21 (GO:0098757) | 3.55E-02 | 239.87 |
| vascular associated smooth muscle cell differentiation (GO:0035886) | 3.55E-02 | 239.87 |
| regulation of MyD88-independent toll-like receptor signaling pathway (GO:0034127) | 3.55E-02 | 239.87 |
| positive regulation of osteoclast differentiation (GO:0045672) | 1.57E-02 | 239.65 |
| positive regulation of alpha-beta T cell proliferation (GO:0046641) | 1.60E-02 | 215.79 |
| regulation of granulocyte macrophage colony-stimulating factor (GO:0032645) | 1.60E-02 | 215.79 |
| regulation of gap junction assembly (GO:1903596) | 4.07E-02 | 197.46 |
| cellular response to interleukin-9 (GO:0071355) | 4.07E-02 | 197.46 |
Top statistically relevant GO biological processes ordered by combined score for NHBE cells using XGBoost.
| GO Biological Processes | ||
|---|---|---|
| regulation of integrin biosynthetic process (GO:0045113) | 1.32E-02 | 8352.53 |
| chronic inflammatory response (GO:0002544) | 1.32E-02 | 8352.53 |
| peptidyl-cysteine S-nitrosylation (GO:0018119) | 1.32E-02 | 8352.53 |
| astrocyte development (GO:0014002) | 1.32E-02 | 6499.56 |
| regulation of macromolecule biosynthetic process (GO:0010556) | 1.32E-02 | 6499.56 |
| astrocyte differentiation (GO:0048708) | 1.32E-02 | 5287.72 |
| leukocyte aggregation (GO:0070486) | 1.32E-02 | 4436.86 |
| peptidyl-cysteine modification (GO:0018198) | 1.32E-02 | 3808.55 |
| defense response to fungus (GO:0050832) | 3.05E-02 | 1111.12 |
| glial cell development (GO:0021782) | 3.05E-02 | 1006.18 |
| positive regulation of intrinsic apoptotic signaling pathway (GO:2001244) | 3.92E-02 | 589.61 |
| regulation of intrinsic apoptotic signaling pathway (GO:2001242) | 3.92E-02 | 425.07 |
| inorganic anion transport (GO:0015698) | 3.92E-02 | 405.46 |
| positive regulation of apoptotic signaling pathway (GO:2001235) | 3.92E-02 | 362.85 |
| pattern recognition receptor signaling pathway (GO:0002221) | 3.92E-02 | 347.96 |
| antimicrobial humoral immune response (GO:0061844) | 3.92E-02 | 327.57 |
| neutrophil chemotaxis (GO:0030593) | 3.92E-02 | 292.57 |
| response to molecule of bacterial origin (GO:0002237) | 3.92E-02 | 277.46 |
| granulocyte chemotaxis (GO:0071621) | 3.92E-02 | 277.46 |
| chloride transport (GO:0006821) | 3.92E-02 | 263.66 |
| positive regulation of growth (GO:0045927) | 3.92E-02 | 263.66 |
| neutrophil migration (GO:1990266) | 3.92E-02 | 259.33 |
| regulation of organelle organization (GO:0033043) | 3.92E-02 | 247.05 |
| activation of endopeptidase activity involved in apoptotic process (GO:0006919) | 3.92E-02 | 243.19 |
| positive regulation of neuron projection development (GO:0010976) | 3.92E-02 | 218.84 |
Top statistically relevant GO biological processes ordered by combined score, for A549 cells (Random Forest).
| GO Biological Processes | ||
|---|---|---|
| RIG-I signaling pathway (GO:0039529) | 2.01E-02 | 819.47 |
| positive regulation of dendritic cell cytokine production (GO:0002732) | 2.08E-02 | 658.60 |
| cytoplasmic pattern recognition receptor signaling in response to virus (GO:0039528) | 3.15E-02 | 463.95 |
| positive regulation of epidermal growth factor-activated receptor activity (GO:0045741) | 3.65E-02 | 401.14 |
| positive regulation of vascular endothelial growth factor production (GO:0010575) | 1.52E-02 | 314.50 |
| regulation of vascular endothelial growth factor production (GO:0010574) | 1.52E-02 | 280.69 |
| positive regulation of nuclear division (GO:0051785) | 1.52E-02 | 280.69 |
| positive regulation of defense response to virus by host (GO:0002230) | 1.52E-02 | 266.02 |
| response to interferon-beta (GO:0035456) | 1.52E-02 | 266.02 |
| regulation of interleukin-2 production (GO:0032663) | 1.52E-02 | 240.53 |
| regulation of defense response to virus by host (GO:0050691) | 2.02E-02 | 183.70 |
| positive regulation of mitotic nuclear division (GO:0045840) | 2.02E-02 | 183.70 |
| positive regulation of interleukin-6 production (GO:0032755) | 1.75E-02 | 120.65 |
| regulation of protein localization to plasma membrane (GO:1903076) | 1.97E-02 | 111.57 |
| defense response to symbiont (GO:0140546) | 1.52E-02 | 98.43 |
| defense response to virus (GO:0051607) | 1.52E-02 | 88.09 |
| negative regulation of cytokine production (GO:0001818) | 1.52E-02 | 84.74 |
| regulation of interleukin-6 production (GO:0032675) | 4.07E-02 | 68.02 |
| cellular response to cytokine stimulus (GO:0071345) | 1.52E-02 | 63.15 |
| positive regulation of cytokine production (GO:0001819) | 2.02E-02 | 45.00 |
| cytokine-mediated signaling pathway (GO:0019221) | 1.52E-02 | 38.92 |
Top statistically relevant GO biological processes ordered by combined score, for A549 cells (XGBoost).
| GO Biological Processes | ||
|---|---|---|
| negative regulation of substrate adhesion-dependent cell spreading (GO:1900025) | 1.49E-02 | 3304.67 |
| negative regulation of cell morphogenesis involved in differentiation (GO:0010771) | 1.49E-02 | 3304.67 |
| protein localization to vacuole (GO:0072665) | 1.49E-02 | 3012.37 |
| regulation of lymphocyte activation (GO:0051249) | 1.49E-02 | 2764.28 |
| negative regulation of T cell receptor signaling pathway (GO:0050860) | 1.49E-02 | 2062.22 |
| regulation of protein localization to cell periphery (GO:1904375) | 1.49E-02 | 1935.63 |
| negative regulation of protein localization to plasma membrane (GO:1903077) | 1.49E-02 | 1822.54 |
| negative regulation of protein localization to cell periphery (GO:1904376) | 1.49E-02 | 1822.54 |
| negative regulation of interleukin-2 production (GO:0032703) | 1.49E-02 | 1720.94 |
| negative regulation of antigen receptor-mediated signaling pathway (GO:0050858) | 1.49E-02 | 1470.20 |
| negative regulation of protein localization to membrane (GO:1905476) | 1.49E-02 | 1400.90 |
| regulation of calcium-mediated signaling (GO:0050848) | 1.49E-02 | 1278.76 |
| regulation of B cell activation (GO:0050864) | 1.49E-02 | 1278.76 |
| regulation of protein localization to membrane (GO:1905475) | 1.50E-02 | 1174.65 |
| regulation of T cell receptor signaling pathway (GO:0050856) | 1.60E-02 | 971.56 |
| regulation of sodium ion transport (GO:0002028) | 1.60E-02 | 938.42 |
| negative regulation of cell-substrate adhesion (GO:0010812) | 1.68E-02 | 824.08 |
| cellular response to tumor necrosis factor (GO:0071356) | 1.49E-02 | 773.33 |
| regulation of interleukin-2 production (GO:0032663) | 1.85E-02 | 657.83 |
| negative regulation of ERK1 and ERK2 cascade (GO:0070373) | 1.85E-02 | 625.39 |
| regulation of substrate adhesion-dependent cell spreading (GO:1900024) | 1.85E-02 | 610.23 |
| interferon-gamma-mediated signaling pathway (GO:0060333) | 2.35E-02 | 426.61 |
| regulation of ion transport (GO:0043269) | 2.45E-02 | 353.55 |
| response to interferon-gamma (GO:0034341) | 2.45E-02 | 348.01 |
| regulation of protein localization to plasma membrane (GO:1903076) | 2.45E-02 | 348.01 |